



Nexstim

**World leader in navigated, non-invasive
brain stimulation therapy and diagnosis**

Martin Jamieson | CEO & Chairman of the Board | Nexstim Plc

Mikko Karvinen | CFO | Nexstim Plc

Corporate Presentation, BioTrinity, London 24 April 2018

 @NexstimOyj

Important information

This document and the information contained herein are being presented by Nexstim Oyj (“**Nexstim**” or the “**Company**”). In connection with any presentation or review of this document, you agree to be bound by the following limitations and notifications.

This document and the information contained herein are being provided to you solely for your information. The distribution of this document in some jurisdictions may be restricted by law and persons into whose possession this document comes are required to inform themselves about and observe any such restrictions. Accordingly, this document may not be distributed in any jurisdiction except under circumstances that will result in compliance with applicable laws and regulations.

This document is not a prospectus, and the information contained herein does not and is not intended to constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities in connection with this document in any jurisdiction. This document and the information contained herein are not an offer of securities in the United States and are not for distribution in the United States.

Recipients should not treat the contents of the document as advice relating to legal, taxation or other matters. This presentation does not purport to be all-inclusive or to contain any or all the information that prospective investors may desire in analysing and deciding whether or not to hold or transact in the Company’s shares. Neither the Company nor any of its affiliates or representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of this document or any of the information contained herein, or any other written or oral communication transmitted or made available to the recipient or its affiliates or representatives. The Company and its affiliates or representatives expressly disclaim to the fullest extent permitted by law any and all liability based, in whole or in part, on this document or any information contained herein or any other written or oral communication transmitted or made available to the recipient or its affiliates or representatives, including, without limitation, with respect to errors therein or omissions therefrom.

Recipients should not assume that the information in this document is accurate as of any date other than the date of this presentation. Nothing contained herein is, or should be relied upon as, a promise or representation as to future performance. The Company does not undertake any obligation to update or revise this this document.

Certain of the information contained herein concerning industry and market data, economic trends, market position and competitiveness is based upon or derived from information provided by third-party consultants and other industry sources. Neither the Company nor any of its affiliates or representatives can guarantee the accuracy of such information or has independently verified the assumptions upon which projections of future trends and performance in such information are based.

Nexstim's NBS System is cleared by the FDA for assessment of the motor and speech cortices for pre-procedural planning. The NBT System is not cleared for commercial distribution in the United States.

FORWARD-LOOKING STATEMENTS

This document may contain forward-looking statements that reflect the Company’s current views with respect to certain future events and potential financial performance. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will materialise. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors. To the extent that this document contains opinions, estimates, forecasts or other forward looking statements, no guarantees or undertakings that these are correct or complete are given by the Company or any of its respective members, advisors, officers or employees or any other person. Forecasts and assumptions which are subject to economic and competitive uncertainty are outside such person’s control and no guarantee can be given that projected results will be achieved or that outcomes will correspond with forecasts. Information in this document may be changed, added to or corrected without advance notification.


Nexstim Plc at a Glance

- We have a pioneering electric (e) field navigated neuro stimulation technology (eTMS)
- Listed in Nasdaq First North Finland & Sweden with about 6000 shareholders
- 93m+ outstanding shares, SITRA largest shareholder
- Independent Board of Directors
- Established sales in US and Europe





E-Field Navigation Differentiates Nexstim TMS

- Unique e-field induced modeling
 - Highly accurate targeting
 - Precise dosing
 - Repeatable over multiple treatment sessions
- Fully integrated system ensures quality and accuracy
 - TMS
 - Proprietary e-field modeling that enables accurate stimulation targeting
 - 3D MRI visualisation and stereotactic navigation
 - EMG response
- Non-invasive and safe




Our Technology – Applications

Technology	Applications – current focus					
Therapy Navigated Brain Therapy (NBT) 	Stroke		Depression		Chronic pain	
	Europe	US	Europe	US	Europe	US
	CE marked	Phase III trial underway	CE marked	FDA cleared	CE marked	Multi-centre clinicals planned
Diagnostic Navigated Brain Stimulation (NBS) 	Pre-surgical mapping – tumour resections					
	Europe	US				
	CE marked	FDA cleared				

NBS Pre-Surgical Mapping significantly improves clinical outcomes

- NBS demonstrates the value of our unique navigation system
- Allows the surgeon to be better prepared and more aggressive with the tumour resection

Progression-free Survival (Months)



¹ Dietmar Frey, Peter Vajkoczy, and Thomas Picht **Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations** Neuro Oncology 2014 : nou110v1-nou110

World Leading Centers Rely on NBS Pre-Surgical Mapping





Nexstim

Navigated Brain Therapy[®]

Reproducible specifically targeted transcranial
stimulation

NBT[®] (Navigated Brain Therapy) has potential for multiple therapeutic applications due to precise navigation

Stroke Rehabilitation Therapy


- E-FIT supplementary Phase III trial underway
- CE marked

Depression Therapy

- CE marked
- FDA cleared

Chronic Pain Therapy

- CE marked



Primary focus is Stroke, Depression and Pain


NBT[®] for depression

- Major depressive disorder affects >300 million people worldwide
- Existing psychotherapy and pharmacological treatment options are suboptimal
- Without navigation, the exact cortex area - Dorso Lateral Pre Frontal Cortex - requiring TMS treatment is correctly targeted in just 30% of patients
- US commercial launch in Q2 2018
- TMS reimbursement is already available at EU markets and in the US




Market opportunity in stroke rehabilitation

2015 Incidence of stroke



2015 Stroke survivors




*Published data

- Large and rapidly growing market
- 50% of stroke survivors will have upper limb paralysis with few available treatment options
- Focus on the period 3 months post stroke

Supplementary E-FIT Trial to Support FDA Clearance

Supplementary E-FIT trial



- 60 patients – 5 leading US centers
- Similar results expected in the active patient group as per the NICHE study which showed a clinically meaningful response in 2/3 of patients
- Active group data from Phase III (NICHE) and supplementary trial to be pooled
- Nexstim expects completion of E-FIT trial in mid-2018
- Expect to file for FDA clearance immediately following results

Highly Supportive Key US Trial Centres based on involvement in the NICHE study



NBT[®] for chronic pain

- 40-50% of neuropathic pain patients are without effective pain relief
- Study conducted by The Walton Centre, UK stated that **44% of patients undergoing NBT therapy reported clinically meaningful pain relief** of at least 3 weeks' duration
- The Walton Centre is currently conducting a follow up study to measure the long term pain relief



Nexstim Milestones

- US launch for depression – Q2 2018
- Complete E-FIT multi-center trial – mid 2018
- File stroke 510k Denovo – H2 2018
- Stroke commercial launch – H1 2019




Nexstim Financing Round to Support Strategic Initiatives

- Timing: H2 2018
- Structure: To be finalized
- Objectives:
 1. Support the US commercial launch of our stroke rehabilitation application
 2. Complete our therapy clinical trial programme



Nexstim Milestones - Clinical trial plan





Nexstim

Thank you